Abstract
Apurinic/apyrimidinic endonuclease 1 (APE1), as a bifunctional enzyme, can not only remove apurinic/apyrimidinic sites (AP-sites) to maintain gene stability but can also regulate the activity of transcription factors. It is an important biomarker of malignant tumours and a new anticancer drug target. However, rapid, simple, and sensitive APE1 detection strategies are still lacking. For this purpose, we designed a molecular gated hyperbranched rolling circle amplification (HRCA) quick sensing system. The identification probe consists of a padlock probe and a ligation probe with an AP-site, which neatly integrates the processes of circular template connection and target-specific recognition. This prevents the Exonuclease III (Exo III) from interfering with the signal. APE1 would swiftly unlock the closed mode and trigger HRCA after excising the AP-site on the identification probe. This would activate the entire system and cause the signal to exhibit exponential amplification in a short period. Under optimized conditions, the system exhibited a favourable linear relationship within the range of 0.0001 to 0.2 U/mL, with a detection limit up to 0.0001 U/mL. Additionally, the technique also performed well in complex human serum and human cell protein extracts, and it may be used to screen APE1 inhibitors and assess the effectiveness of inhibition. The molecular gated HRCA quick sensing method presented herein would help in the development of new anticancer medications and has potential therapeutic applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.